Abstract: A data processing system implements receiving a first input in a spreadsheet in a spreadsheet application, detecting an indication that the first input includes first executable program code, analyzing the first executable program code to identify first references to one or more first elements of the spreadsheet in the first executable program code, requesting spreadsheet data associated with the one or more first elements of the spreadsheet from the spreadsheet application, receiving the spreadsheet data from the spreadsheet application; executing the first executable program code using the spreadsheet data referenced in the first executable program code to obtain a first program code result and causing the spreadsheet application to display the first program code result in the spreadsheet application.

Abstract: In an illustrative embodiment, systems and methods for determining exposure include detecting, based on received data from external entities, an occurrence of a catastrophic event. Responsive to detecting the occurrence, a first matrix is generated indicating features of one or more properties within a vicinity of the catastrophic event, and a second matrix is generated representing characteristics of the catastrophic event. Using the first matrix and the second matrix, a convolution calculation matrix is calculated indicating amounts of correspondence between the first matrix and the second matrix. In real time, in response to detecting the occurrence of the catastrophic event, risk exposure information is presented to at least one remote computing system associated with at least one property of the plurality of properties, where the risk exposure data relates to the amount of correspondence between the first matrix and the second matrix in reference to the at least one property.

Abstract: In an illustrative embodiment, systems and methods for determining exposure include detecting, based on received data from external entities, an occurrence of a catastrophic event. Responsive to detecting the occurrence, a first matrix is generated indicating features of one or more properties within a vicinity of the catastrophic event, and a second matrix is generated representing characteristics of the catastrophic event. Using the first matrix and the second matrix, a convolution calculation matrix is calculated indicating amounts of correspondence between the first matrix and the second matrix. In real time, in response to detecting the occurrence of the catastrophic event, present risk exposure information to at least one remote computing system associated with at least one property of the plurality of properties, where the risk exposure data relates to the amount of correspondence between the first matrix and the second matrix in reference to the at least one property.

Abstract: A dashboard interface, platform and environment for supporting transactions and deriving insights therefrom, in a preferred embodiment, includes a pipeline report graphical user interface including rows identifying renewal opportunities, row each involving a client and product, an interest registration graphical user interface for registering interest in a particular renewal opportunity presented in the pipeline report graphical user interface, a stages of interest tracking graphical user interface for tracking negotiation progress between a client and a provider, and a detailed interest tracking graphical user interface for tracking negotiation details related to the particular renewal opportunity.

Abstract: Systems and methods of the present technology provide the capability to adjust historical claim frequency and/or claim severity data using a weather score process.

Abstract: Systems and methods of the present technology provide the capability to determine risk exposure of points of interest (e.g., insured locations) based on the occurrence of an event (e.g., a catastrophic event). The systems and methods use two-dimensional convolution and FFT processing to provide quick determinations.

Abstract: Disclosed are implant compositions and methods for treatment of neurological diseases of the central nervous system of a mammal.

Abstract: The present invention is directed to the use of choroid plexus cells and/or choroid plexus conditioned media for enhancing the growth, survival and/or maintenance of function of non-choroid plexus cells grown in long term or short term culture.

Abstract: There is described a process for the manufacture of a racemic 2-aryl propionic acid compound, or a pharmaceutically acceptable salt thereof, which comprises reacting the S- or R-enantiomer of the corresponding 2-aryl propionic acid compound with a base.

Abstract: Disclosed are implant compositions and methods for treatment of neurological diseases of the central nervous system of a mammal.

Abstract: The present invention is directed to a composition comprising high mannuronic acid-containing alginate and a polycation having a polydispersity index of less than 1.5. The composition is particularly useful for making biocompatible microcapsules containing living cells for allo- or xeno-transplantation. Such microcapsules have enhanced durability and can maintain their structural and functional integrity over long periods of time compared to prior art alginate microcapsules.

Abstract: A “supplementary choroid plexus” comprising preferably a xenotransplant of choroid plexus cells from a neonatal mammal provides a steady supply of trophic factors for administration to a central nervous system in need of treatment for a neurological disease. Choroid plexus cells manufacture a range of trophic factors, particularly during fetal development. This neurotrophic factor therapy may be useful in treating clinical and subclinical neurodegenerative diseases particularly those in which the choroid plexus has often become atrophic. The xenotransplant is cloaked in a protective layer (such as of alginate) capable of concealing the foreign nature of the transplant. Lateral ventricles are the preferred implantation site, from where the trophic factors are carried through the neuropil by the circulation of cerebrospinal fluid.

Abstract: The present invention is directed to the prevention or treatment of autoimmune diseases, and in particular, of type I diabetes, by administering a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

Abstract: The present invention is directed to the use of choroids plexus cells and/or choroids plexus conditioned media for enhancing the growth, survival and/or maintenance of function of non-choroid plexus cells grown in long term or short term culture.

Abstract: Disclosed are compositions and methods for the xenotransplantation treatment of neurological diseases of the central nervous system of a mammal.

Abstract: The invention relates to a novel method of administration, and device employed in the method, for administering a treatment species to the lungs of a recipient patient. The method involves introducing the device of the invention to the venous system of the patient, the size of the treatment species being such that, upon introduction to the venous system of the patient, the device will impact in a region of a lung capillary of the patient. The treatment species gains access to the lung and/or lung epithelia due to proteases associated with the treatments species. The application of the method to the treatment of cystic fibrosis is also claimed.

Abstract: The present invention is directed to the use of choroid plexus cells and/or choroid plexus conditioned media for enhancing the growth, survival and/or maintenance of function of non-choroid plexus cells grown in long term or short term culture.

Abstract: Aggregates and their method of preparation suitable for implantation into a recipient in order to produce insulin in vivo. The methods involve culturing islet cells isolated from the pancreas of donor piglets with isolated Sertoli cells from the testes of donor piglets. A preferred period of culturing is 5 days and may be followed by a purification procedure.

Abstract: The present invention is directed to the prevention or treatment of sensorineural hearing loss by administering a therapeutically effective amount of an implantable composition comprising encapsulated living choroid plexus cells.

Abstract: An organic polymer having a plurality of regions along the length of the polymer backbone and comprising two or more of the following a first region for transporting negative charge carriers and having a first bandgap defined by a first LUMO level and a first HOMO level; and a second region for transporting positive charge carriers and having a second bandgap defined by a second LUMO level and a second HOMO level; and a third region for accepting and combining positive and negative charge carriers to generate light and having a third bandgap defined by a third LUMO level and a third HOMO level, wherein each region comprises one or more monomers and the quantity arrangement of the monomers in the organic polymer is selected so that the first, second and third bandgaps are distinct from one another in the polymer.